Suppr超能文献

负载膜不通透性肽AC3-I的纳米颗粒的制备及其对心肌缺血再灌注的保护作用

Preparation of Nanoparticles Loaded with Membrane-Impermeable Peptide AC3-I and Its Protective Effect on Myocardial Ischemia and Reperfusion.

作者信息

Liu Yi, Niu Yingyi, Zhang Wenjie, Wang Kaikai, Liu Tianqing, Zhu Weizhong

机构信息

School of Pharmacy, Nantong University, Nantong 226001, China.

NICM Health Research Institute, Western Sydney University, Sydney, NSW 2145, Australia.

出版信息

Pharmaceutics. 2024 Mar 18;16(3):416. doi: 10.3390/pharmaceutics16030416.

Abstract

PURPOSE

It is well known that inhibition of Ca/calmodulin-dependent protein kinase II (CaMKII) provides cardiac protection in cases of myocardial ischemia-reperfusion injury. However, there are currently no cytoplasm-impermeable drugs that target CaMKII. The aim of this study was to develop curcumin albumin nanoparticles (HSA-CCM NPs) containing AC3-I and investigate their protective effects on hypoxia-reoxygenation (H/R)-induced injuries in adult rat cardiomyocytes and ischemia-reperfusion (I/R) injuries in isolated rat hearts.

METHODS

HSA-CCM NPs were synthesized using β-ME methods, while the membrane-impermeable peptide AC3-I was covalently linked via a disulfide bond to synthesize AC3-I@HSA-CCM NPs (AC3-I@NPs). Nanoparticle stability and drug release were characterized. To assess the cardiomyocyte uptake of AC3-I@NPs, AC3-I@NPs were incubated with cardiomyocytes under normoxia and hypoxia, respectively. The cardioprotective effect of AC3-I@NPs was determined by using a lactate dehydrogenase kit (LDH) and PI/Hoechst staining. The phosphorylation of phospholamban (p-PLB) was detected by Western blotting in hypoxia-reoxygenation and electric field stimulation models. To further investigate the protective role of AC3-I@NPs against myocardial ischemia-reperfusion injury, we collected coronary effluents and measured creatine kinase (CK) and LDH release in Langendorff rat hearts.

RESULTS

AC3-I@NPs were successfully prepared and characterized. Both HSA-CCM NPs and AC3-I@NPs were taken up by cardiomyocytes. AC3-I@NPs protected cardiomyocytes from injury caused by hypoxia-reoxygenation, as demonstrated by decreased cardiomyocyte death and LDH release. AC3-I@NPs reduced p-PLB levels evoked by hypoxia-reoxygenation and electrical field stimulation in adult rat cardiac myocytes. AC3-I@NPs decreased the release of LDH and CK from coronary effluents.

CONCLUSIONS

AC3-I@NPs showed protective effects against myocardial injuries induced by hypoxia-reoxygenation in cardiomyocytes and ischemia-reperfusion in isolated hearts.

摘要

目的

众所周知,抑制钙/钙调蛋白依赖性蛋白激酶II(CaMKII)可在心肌缺血再灌注损伤的情况下提供心脏保护作用。然而,目前尚无靶向CaMKII的不能透过细胞质的药物。本研究的目的是开发含有AC3-I的姜黄素白蛋白纳米颗粒(HSA-CCM NPs),并研究其对成年大鼠心肌细胞缺氧复氧(H/R)诱导的损伤以及离体大鼠心脏缺血再灌注(I/R)损伤的保护作用。

方法

采用β-ME法合成HSA-CCM NPs,同时通过二硫键将不能透过细胞膜的肽AC3-I共价连接以合成AC3-I@HSA-CCM NPs(AC3-I@NPs)。对纳米颗粒的稳定性和药物释放进行了表征。为了评估AC3-I@NPs对心肌细胞的摄取,分别在常氧和缺氧条件下将AC3-I@NPs与心肌细胞孵育。使用乳酸脱氢酶试剂盒(LDH)和PI/Hoechst染色来确定AC3-I@NPs的心脏保护作用。在缺氧复氧和电场刺激模型中,通过蛋白质印迹法检测受磷蛋白(p-PLB)的磷酸化。为了进一步研究AC3-I@NPs对心肌缺血再灌注损伤的保护作用,我们收集了冠状动脉流出液,并测量了Langendorff大鼠心脏中肌酸激酶(CK)和LDH的释放。

结果

成功制备并表征了AC3-I@NPs。HSA-CCM NPs和AC3-I@NPs均被心肌细胞摄取。AC3-I@NPs保护心肌细胞免受缺氧复氧引起的损伤,表现为心肌细胞死亡减少和LDH释放降低。AC3-I@NPs降低了成年大鼠心肌细胞中缺氧复氧和电场刺激引起的p-PLB水平。AC3-I@NPs减少了冠状动脉流出液中LDH和CK的释放。

结论

AC3-I@NPs对心肌细胞缺氧复氧诱导的损伤以及离体心脏缺血再灌注诱导的损伤具有保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1a7/10974440/3e7b5ce59b92/pharmaceutics-16-00416-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验